Protection by a polyvalent influenza vaccine and persistence of homologous and heterologous HI antibodies during a period of two epidemic seasons.
A split-product influenza A vaccine which contained an influenza B strain (B/Hong Kong/8/73) and two influenza A strains, antigenically identical with A/Fort Dix/741/76 (Hsw1N1) and A/Victoria/3/75 (H3N2), was offered to personnel of the CPHL. Changes in the antibody status were followed with serum samples collected from 153 participants on the day of vaccination and 1, 13 and 18 months thereafter. During the two epidemic seasons in the trial period there were only four serological influenza A infections (2.6%) among the vaccinees. This is one eighth of the corresponding infection rate (22%) in the general population estimated on the basis of other indices. The vaccinees' antibody response was strongly influenced by the age of the individual subjects. During the trial period the decrease in the antibody titres slowed down. The geometric mean titres of homologous HI antibodies were still substantially higher at the end of the period than at the beginning. This also applied to heterologous antibodies against H1N1 viruses in persons born between 1926 and 1952. In participants born after 1952, the vaccine was not able to evoke these antibodies, and in participants born in or before 1925 the boosting effect was poor.
D000328:Adult; D000367:Age Factors; D000914:Antibodies, Viral / Q000302:isolation & purification*; D004196:Disease Outbreaks; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D009980:Influenza A virus / Q000276:immunology; D007252:Influenza Vaccines / Q000276:immunology* / Q000627:therapeutic use; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control; D008297:Male; D008875:Middle Aged
D000914:Antibodies, Viral; D007252:Influenza Vaccines